Cerity Partners LLC Boosts Position in Novo Nordisk A/S (NYSE:NVO)

Cerity Partners LLC lifted its position in Novo Nordisk A/S (NYSE:NVO) by 29.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 790,636 shares of the company’s stock after buying an additional 181,933 shares during the quarter. Cerity Partners LLC’s holdings in Novo Nordisk A/S were worth $94,141,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of NVO. 1620 Investment Advisors Inc. bought a new position in Novo Nordisk A/S in the 2nd quarter worth about $25,000. Strategic Investment Solutions Inc. IL purchased a new stake in Novo Nordisk A/S in the second quarter valued at approximately $25,000. Gilliland Jeter Wealth Management LLC lifted its position in Novo Nordisk A/S by 200.0% during the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after purchasing an additional 120 shares during the last quarter. Halpern Financial Inc. grew its stake in Novo Nordisk A/S by 113.0% in the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock worth $30,000 after buying an additional 113 shares in the last quarter. Finally, Abound Wealth Management increased its holdings in shares of Novo Nordisk A/S by 257.4% in the 2nd quarter. Abound Wealth Management now owns 218 shares of the company’s stock worth $31,000 after buying an additional 157 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of recent research reports. BMO Capital Markets reduced their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $144.50.

Novo Nordisk A/S Trading Up 2.4 %

Shares of NVO stock opened at $105.07 on Friday. The stock has a fifty day simple moving average of $115.48 and a two-hundred day simple moving average of $128.79. Novo Nordisk A/S has a 52-week low of $94.73 and a 52-week high of $148.15. The firm has a market capitalization of $471.50 billion, a PE ratio of 34.00, a PEG ratio of 1.32 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.